Choosing Wisely: What CancerTests and Treatments Do You Really Need?

Oncologists have joined eight other physician specialty organizations in the Choosing Wisely® campaign with a list of the Top Five Cancer-Related Tests, Procedures, and Treatments That Many Patients Do Not Need. Choosing Wisely asked each of the specialist groups to come up with a list of five things doctors and patients should question in order to…  Read More

Fight Colorectal Cancer Headed for San Francisco and the 2012 GI Symposium

We’re getting ready for the 2012 Gastrointestinal Cancers Symposium next week at the Moscone Center in San Francisco. Kim Ryan, Nancy Roach, and I will be there checking out the latest colon and rectal cancer prevention and treatment research and talking with leaders in the colorectal cancer field. Colon and rectal cancer is featured on Saturday,…  Read More

Doctors Urged to Talk Discuss Palliative Care

Soon after diagnosing a patient with advanced cancer, a doctor should begin discussing options for palliative care—the management of symptoms—according to a new policy statement from the American Society of Clinical Oncology (ASCO).  ASCO also released a new, free guide called Advanced Cancer Care Planning for patients to help initiate those conversations.

Young People with Advanced Colorectal Cancer Do As Well with Chemotherapy as Older Patients

When colorectal cancer spreads to other parts of the body, young people under 50 who get chemotherapy benefit as much as those who are older. With drug combinations, there is no difference between those under 50 and those who are 50 and older in responding to chemotherapy, how long it takes before cancer gets worse, or…  Read More

ASCO Advises Oncologists: Test for KRAS Mutations

The American Society for Clinical Oncology (ASCO) has published a provisional clinical opinion (PCO) advising doctors to test patients with colorectal cancer for KRAS mutations before treating them with medicines that include Erbitux® (cetuximab) or Vectibix™ (panitumumab). The consensus of experts who reviewed recent research was that patients with metastatic colorectal cancer whose tumors have mutations in…  Read More

ASCO Issues Opinion on KRAS Testing

An panel of experts at the American Society of Clinical Oncology recommends that all patients who are being considered for anti-EGFR therapy have their tumors tested for the KRAS gene. If mutations are found, the panel says they should not be treated with Erbitux® (cetuximab) or Vectibix™ (panitumumab).